Summary
Islet amyloid polypeptide is a normal constituent of islet Beta cells and is derived from a larger precursor by removal of flanking peptides at the carboxy (C) and amino (N) terminals. The role of these flanking peptides in the formation of amyloid in Type 2 (non-insulin-dependent) diabetes mellitus and in insulinomas is unknown. The C-terminal flanking peptide of islet amyloid polypeptide was localised by immunocytochemistry in human and monkey pancreatic islets from Type 2 diabetic and non-diabetic individuals by use of specific polyclonal antisera. Immunoreactivity for the C-terminal peptide was found in insulincontaining cells in both diabetic and non-diabetic tissue: no antibody binding was detected in islet amyloid of Type 2 diabetic man or of monkeys although a positive reaction occurred with antisera for islet amyloid polypeptide. The C-terminal peptide was localised by immunogold electron microscopy in the insulin granules in both diabetic and nondiabetic individuals but, unlike islet amyloid polypeptide, was not detected in lysosomes. The absence of immunoreactivity for the C-terminal peptide in amyloid suggests that incomplete cleavage of this flanking peptide from islet amyloid polypeptide is not a factor in the formation of islet amyloid.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD, Johnson KH (1987) Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuro-peptide-like protein also present in normal islet cells. Proc Natl Acad Sci 84: 3881–3885
Clark A, Edwards CA, Ostle LR, Sutton R, Rothbard JB, Morris JF, Turner RC (1989) Localisation of islet amyloid peptide in lipofuscin bodies and secretory granules of human B eta-cells and in islets of Type 2 diabetic subjects. Cell Tissue Res 257: 179–185
Sanke T, Bell GI, Sample C, Rubenstein AH, Steiner DF (1988) An islet amyloid peptide is derived from an 89 amino acid precursor by proteolytic processing. J Biol Chem 263: 17243–17246
Nishi M, Bell GI, Steiner DF (1990) Islet amyloid polypeptide (amylin): no evidence of an abnormal precursor sequence in 25 Type 2 (non-insulin-dependent) diabetic patients. Diabetologia 33: 628–630
Westermark P, Engström U, Westermark GT, Johnson KH, Permerth J, Betzholtz C (1989) Islet amyloid polypeptide (IAPP) and Pro IAPP immunoreactivity in human islet of Langerhans. Diabetes Res Clin Prac 7: 219–226
Conlon JM, Grimelius L, Thin L (1988) Structural charaterisation of a high-molecular-mass form of calcitonin procalci-tonin-(60–116)-peptide and its corresponding N-terminal flanking peptide procalcitonin (1–57) peptide in a human medullary thyroid carcinoma. Biochem J 256: 245–250
Roos BA, Huber B, Birnbaum RS, Aron DC, Lundall AW, Lips K, Baylin SB (1983) Medullary thyroid carcinomas secrete a noncalcitonin peptide corresponding to the carboxy-terminal region of procalcitonin. J Clin Endocrinol Metab 56: 802–807
Hutton JC (1989) The insulin secretory granule. Diabetologia 32: 271–281
Clark A, Matthews DR, Naylor BA, Wells CA, Hosker JP, Turner RC (1987) Pancreatic islet amyloid and elevated proinsulin secretion in familial maturity onset diabetes. Diabetes Research 4: 51–55
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Clark, A., Lloyd, J., Novials, A. et al. Localisation of islet amyloid polypeptide and its carboxy terminal flanking peptide in islets of diabetic man and monkey. Diabetologia 34, 449–451 (1991). https://doi.org/10.1007/BF00403186
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00403186